GlaxoSmithKline, Medicago Covid-19 Vaccine Heads to Phase 3 Trial
March 16 2021 - 6:58AM
Dow Jones News
By Matt Grossman
GlaxoSmithKline PLC and Medicago are beginning a Phase 3 trial
to test a Covid-19 vaccine that they are developing, the companies
said Tuesday.
Canada-based Medicago is responsible for the vaccine to be
tested in the trial, while GlaxoSmithKline developed the adjuvant.
In the trial, two doses will be given 21 days apart. Up to 30,000
people will be enrolled in the placebo-controlled study.
Medicago has also begun a study to explore developing an
additional vaccine candidate to address Covid-19 variants.
The decision to begin a Phase 3 trial portion follows positive
interim Phase 2 results, Medicago and GlaxoSmithKline said. Full
results from the Phase 2 portion will be available next month,
according to the companies.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
March 16, 2021 07:43 ET (11:43 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Sep 2024 to Oct 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2023 to Oct 2024